Teleflex Inc. (NYSE:TFX) – Equities researchers at KeyCorp reduced their FY2016 EPS estimates for Teleflex in a research report issued on Tuesday. KeyCorp analyst M. Mishan now expects that the firm will post earnings of $7.29 per share for the year, down from their prior forecast of $7.30. KeyCorp also issued estimates for Teleflex’s Q4 2016 earnings at $2.08 EPS and FY2017 earnings at $7.83 EPS.
Several other research firms have also commented on TFX. Zacks Investment Research lowered shares of Teleflex from a “hold” rating to a “sell” rating in a report on Tuesday, November 1st. Jefferies Group reissued a “hold” rating and issued a $155.00 target price (up from $154.00) on shares of Teleflex in a report on Tuesday, December 6th. Finally, Stephens lowered shares of Teleflex from an “overweight” rating to an “equal weight” rating in a report on Friday, October 28th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $174.25.
Shares of Teleflex (NYSE:TFX) opened at 166.03 on Thursday. The stock has a market cap of $7.31 billion, a price-to-earnings ratio of 28.68 and a beta of 0.90. Teleflex has a 1-year low of $130.84 and a 1-year high of $188.79. The company has a 50-day moving average price of $159.76 and a 200-day moving average price of $167.30.
Teleflex (NYSE:TFX) last posted its earnings results on Thursday, October 27th. The medical technology company reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.78 by $0.02. Teleflex had a return on equity of 15.66% and a net margin of 15.09%. The firm had revenue of $455.60 million for the quarter, compared to analyst estimates of $461.80 million. During the same quarter in the prior year, the company earned $1.60 EPS. Teleflex’s revenue was up 2.7% on a year-over-year basis.
Large investors have recently bought and sold shares of the company. New York State Teachers Retirement System raised its stake in Teleflex by 5.3% in the second quarter. New York State Teachers Retirement System now owns 77,046 shares of the medical technology company’s stock worth $13,661,000 after buying an additional 3,900 shares during the last quarter. Rice Hall James & Associates LLC raised its stake in Teleflex by 0.6% in the second quarter. Rice Hall James & Associates LLC now owns 75,130 shares of the medical technology company’s stock worth $13,321,000 after buying an additional 411 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in Teleflex by 1.2% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,297,977 shares of the medical technology company’s stock worth $218,125,000 after buying an additional 15,233 shares during the last quarter. American International Group Inc. increased its position in shares of Teleflex by 0.8% in the third quarter. American International Group Inc. now owns 85,031 shares of the medical technology company’s stock worth $14,289,000 after buying an additional 637 shares during the period. Finally, Icon Advisers Inc. Co. purchased a new position in shares of Teleflex during the third quarter worth about $2,067,000. 93.06% of the stock is currently owned by hedge funds and other institutional investors.
In other Teleflex news, Director Jeffrey A. Graves sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 21st. The shares were sold at an average price of $160.57, for a total transaction of $802,850.00. Following the sale, the director now directly owns 13,022 shares of the company’s stock, valued at approximately $2,090,942.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.15% of the company’s stock.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company markets and sells its products to hospitals and healthcare providers, across the world, through a combination of its direct sales force and distributors.